Joris Mallard, Elyse Hucteau, Laura Bender, Fabien Moinard-Butot, Emma Rochelle, Lauréline Boutonnet, Antoine Grandperrin, Roland Schott, Carole Pflumio, Philippe Trensz, Michal Kalish-Weindling, Anne-Laure Charles, Bernard Gény, Fabrice Favret, Xavier Pivot, Thomas J Hureau, Allan F Pagano
BACKGROUND: Breast cancer patients are commonly treated with sequential administrations of epirubicin-cyclophosphamide (EC) and paclitaxel (TAX). The chronic effect of this treatment induces skeletal muscle alterations, but the specific effect of each chemotherapy agent is unknown. This study aimed to investigate the effect of EC or TAX administration on skeletal muscle homeostasis in breast cancer patients. METHODS: Twenty early breast cancer patients undergoing EC followed by TAX chemotherapies were included...
January 6, 2024: Journal of Cachexia, Sarcopenia and Muscle